Clinical Trials in Tennessee

Showing 7541-7560 of 15,329 trials

ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study

NCT02021279

The primary objective of this study is to assess the safety and effectiveness of MatriStem Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. Patients are evaluated throughout a 3 year follow-up period.

Pelvic Organ Prolapse

Integra LifeSciences Corporation161 participantsStarted Jun 2014

Stanford, California, United States • Weston, Florida, United States • Grand Rapids, Michigan, United States +10 more locations

COMPLETEDPhase 316 miles

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

NCT00326898

This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib malate is more effective than sorafenib tosylate or placebo in treating kidney cancer.

Clear Cell Renal Cell CarcinomaStage I Renal Cell Cancer AJCC v6 and v7Stage II Renal Cell Cancer AJCC v7+1 more

National Cancer Institute (NCI)1,943 participantsStarted Apr 2006

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Mobile, Alabama, United States +984 more locations

ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

Find Trials by Condition in Tennessee

X-82 to Treat Age-related Macular Degeneration

SeRenade Parent-Child Music Class Program

Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in Patients

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

Novel Cardiac Signal Processing System

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer